Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorFred Friedberg

About this trial

This is a 16-week controlled treatment trial of an over-the -counter supplement, hydrogen water, for individuals with ME/CFS patients. An active treatment condition will be compared to a placebo-control condition. The study will also seek confirmation of heart rate variability (HRV) as a biomarker, that is, as a predictor of improvement vs. non-improvement to be assessed at treatment termination. The HRV biomarker hypothesis is based on a finding that High Frequency HRV (cardio-parasympathetic measure) biologically separated improvers and non-improvers in my previous ME/CFS observational study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18-65 of both sexes

considered physically capable and willing to perform the study tasks

Meet validated phone-screen eligibility for ME/CFS criteria

Participant has internet and computer

Disqualifiers

Cases of fatigue clearly attributable to self-report medical conditions such as untreated hypothyroidism, unstable diabetes mellitus, organ failure, chronic infections, and chronic inflammatory diseases, or AIDS. Kidney disease/renal failure is also an exclusion

Exclusionary psychiatric disorders include any psychosis, or alcohol/ substance abuse within two years prior to illness onset and any time afterward, and current or past depression with melancholic or psychotic features within 5 years prior to onset of ME/CFS or anytime afterward

Pregnancy is an exclusion.

Patients with BMI>35

Trial design

Design model

Parallel

Treatments tested in this trial

  • Placebo condition

    Dietary supplement

    16 week intervention of magnesium pill without active ingredient of molecular hydrogen.

  • Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.

    Dietary supplement

    The 3 daily doses of molecular hydrogen scheduled for a 16 week intervention. This distinguishes it from the placebo comparator condition.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Placebo conditionPlacebo comparator 1 intervention
Group B: Active hydrogen water interventionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Fatigue Severity Scale

Self-report measure of the effect of fatigue on functioning.

Time frame
2 weeks.

Secondary outcomes

1

SF-36 Physical Function Subscale

Self-report measure of how much health limits your ability to perform various types of physical activities.

Time frame
30 days
2

Depression, Anxiety and Stress Scale

Self-report measures three related negative emotional states of depression, anxiety, and tension/stress.

Time frame
30 days
3

Hassles and Uplifts Scale

Self-report measure of chronic minor stressors and positive everyday experiences.

Time frame
2 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fred Friedberg

Lead sponsor

Stony Brook University

Sponsor institution